Alnylam Pharmaceuticals, Inc. ALNY announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1), in development for the treatment of acute hepatic porphyria (AHP).
The MAA was supported by data from the pivotal ENVISION phase III study. In the study, givosiran met the primary efficacy endpoint, with a 74% mean reduction relative to placebo in the annualized rate of composite porphyria attacks. There was a corresponding 90% median reduction in composite annualized attack rate (AAR), with a median AAR of 1.0 in givosiran patients compared with that of 10.7 in placebo patients. In the trial, 50% of givosiran-treated patients were attack free during the six-month treatment period compared to 16.3% of placebo-treated patients.
Givosiran previously received Breakthrough Therapy designation and Orphan Drug status from the FDA for AHP. The drug has also been granted Priority Medicines (PRIME) designation and Orphan Drug status by the EMA for the same.
In June 2019, the company also completed the rolling submission of a new drug application (NDA) to the FDA for givosiran in AHP.
Shares of Alnylam have declined 1.3% year to date against the industry’s growth of 7.4%.
We remind investors that Onpattro, a first-of-its-kind RNAi therapeutic, is the company’s only approved drug. It is also the only FDA-approved drug for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.
The company also has other candidates in its pipeline. Alnylam along with partner The Medicine Company MDCO is evaluating inclisiran in phase III ORION studies for hypercholesterolemia.
Alnylam’s expertise in RNAi therapeutics and broad intellectual property estate have allowed it to enter collaborations with leading pharmaceutical and life sciences companies, including Ionis Pharmaceuticals, Novartis NVS, Roche RHHBY, Takeda, Merck and Sanofi’s specialty care global business unit, Genzyme, among others.
Alnylam Pharmaceuticals, Inc. Price
Alnylam Pharmaceuticals, Inc. price | Alnylam Pharmaceuticals, Inc. Quote
Alnylam currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
This Could Be the Fastest Way to Grow Wealth in 2019
Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities.
These companies are changing the world – and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98%, +119% and +164% gains in as little as 1 month.
Click here to see these breakthrough stocks now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novartis AG (NVS) : Free Stock Analysis Report
Roche Holding AG (RHHBY) : Free Stock Analysis Report
The Medicines Company (MDCO) : Free Stock Analysis Report
Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research